These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 34580930)

  • 1. Efficacy and safety of conventional antiviral agents in preventive strategies for cytomegalovirus infection after kidney transplantation: a systematic review and network meta-analysis.
    Ruenroengbun N; Numthavaj P; Sapankaew T; Chaiyakittisopon K; Ingsathit A; Mckay GJ; Attia J; Thakkinstian A
    Transpl Int; 2021 Dec; 34(12):2720-2734. PubMed ID: 34580930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Antiviral Agents in Preventing Allograft Rejection Following CMV Prophylaxis in High-Risk Kidney Transplantation: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Ruenroengbun N; Sapankaew T; Chaiyakittisopon K; Phoompoung P; Ngamprasertchai T
    Front Cell Infect Microbiol; 2022; 12():865735. PubMed ID: 35433502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
    Hodson EM; Ladhani M; Webster AC; Strippoli GF; Craig JC
    Cochrane Database Syst Rev; 2013 Feb; (2):CD003774. PubMed ID: 23450543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.
    Noble S; Faulds D
    Drugs; 1998 Jul; 56(1):115-46. PubMed ID: 9664203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A split strategy to prevent cytomegalovirus after kidney transplantation using prophylaxis in serological high-risk patients and a pre-emptive strategy in intermediate-risk patients: Combining the best of two options?
    Hellemans R; Wijtvliet V; Bergs K; Philipse E; Vleut R; Massart A; Couttenye MM; Matheeussen V; Abramowicz D
    Transpl Infect Dis; 2021 Apr; 23(2):e13467. PubMed ID: 32935909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus infection in heart transplantation: A single center experience.
    Echenique IA; Angarone MP; Rich JD; Anderson AS; Stosor V
    Transpl Infect Dis; 2018 Aug; 20(4):e12896. PubMed ID: 29602266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human cytomegalovirus and kidney transplantation: a clinician's update.
    De Keyzer K; Van Laecke S; Peeters P; Vanholder R
    Am J Kidney Dis; 2011 Jul; 58(1):118-26. PubMed ID: 21684438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation.
    Reischig T; Hribova P; Jindra P; Hes O; Bouda M; Treska V; Viklicky O
    J Am Soc Nephrol; 2012 Sep; 23(9):1588-97. PubMed ID: 22917575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Prophylaxis vs Pre-emptive Approach for Cytomegalovirus Infection in Kidney Transplant Recipients.
    Kır O; Zeytinoğlu A; Arda B; Yılmaz M; Aşçı G; Töz H
    Transplant Proc; 2017 Apr; 49(3):537-540. PubMed ID: 28340829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
    Hodson EM; Barclay PG; Craig JC; Jones C; Kable K; Strippoli GF; Vimalachandra D; Webster AC
    Cochrane Database Syst Rev; 2005 Oct; (4):CD003774. PubMed ID: 16235341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice.
    Fernández-Ruiz M; Arias M; Campistol JM; Navarro D; Gómez-Huertas E; Gómez-Márquez G; Díaz JM; Hernández D; Bernal-Blanco G; Cofan F; Jimeno L; Franco-Esteve A; González E; Moreso FJ; Gómez-Alamillo C; Mendiluce A; Luna-Huerta E; Aguado JM;
    Transpl Int; 2015 Sep; 28(9):1042-54. PubMed ID: 25864986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of cytomegalovirus disease in high-risk liver transplant recipients on valganciclovir prophylaxis: a systematic review and meta-analysis.
    Kalil AC; Mindru C; Botha JF; Grant WJ; Mercer DF; Olivera MA; McCartan MA; McCashland TM; Langnas AN; Florescu DF
    Liver Transpl; 2012 Dec; 18(12):1440-7. PubMed ID: 22887929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Efficacy and Safety of Different Antiviral Agents for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis.
    Gagelmann N; Ljungman P; Styczynski J; Kröger N
    Biol Blood Marrow Transplant; 2018 Oct; 24(10):2101-2109. PubMed ID: 29777868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
    Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus High-risk Kidney Transplant Recipients Show No Difference in Long-term Outcomes Following Preemptive Versus Prophylactic Management.
    Blom KB; Birkeland GK; Midtvedt K; Jenssen TG; Reisæter AV; Rollag H; Hartmann A; Sagedal S; Sjaastad I; Tylden G; Njølstad G; Nilsen E; Christensen A; Åsberg A; Birkeland JA
    Transplantation; 2023 Aug; 107(8):1846-1853. PubMed ID: 37211633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New developments in the management of cytomegalovirus infection after solid organ transplantation.
    Eid AJ; Razonable RR
    Drugs; 2010 May; 70(8):965-81. PubMed ID: 20481654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
    Hodson EM; Craig JC; Strippoli GF; Webster AC
    Cochrane Database Syst Rev; 2008 Apr; (2):CD003774. PubMed ID: 18425894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease.
    Taber DJ; Ashcraft E; Baillie GM; Berkman S; Rogers J; Baliga PK; Rajagopalan PR; Lin A; Emovon O; Afzal F; Chavin KD
    Transpl Infect Dis; 2004 Sep; 6(3):101-9. PubMed ID: 15569225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-emptive intravenous ganciclovir versus valganciclovir prophylaxis for de novo cytomegalovirus-seropositive kidney-transplant recipients.
    Weclawiak H; Kamar N; Mengelle C; Esposito L; Mohamed AO; Lavayssiere L; Ribes D; Cointault O; Nogier MB; Cardeau-Desangles I; Izopet J; Rostaing L
    Transpl Int; 2010 Oct; 23(10):1056-64. PubMed ID: 20477997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients.
    Reischig T; Nemcová J; Vanecek T; Jindra P; Hes O; Bouda M; Treska V
    Antivir Ther; 2010; 15(1):23-30. PubMed ID: 20167988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.